GlassScriptPhysician profile
Swee Jian Ngeow
NPI 1952568248
$4,985.03
in general payments reported to CMS, 2019-2025
71 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $617 · 2021: $643 · 2022: $449 · 2023: $843 · 2024: $900 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $637.71 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $381.10 | 2019-2025 | |
| Incyte Corporation | $319.59 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Stemline Therapeutics INC. | $226.27 | 2023-2025 | Orserdu |
| Pfizer INC. | $186.53 | 2019-2025 | |
| Amgen INC. | $173.19 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| E.R. Squibb & Sons, L.L.C. | $166.81 | 2019-2025 | Opdivo, Krazati |
| Glaxosmithkline, LLC. | $158.05 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $142.21 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Abbvie INC. | $135.70 | 2021-2025 | |
| Genzyme Corporation | $135.47 | 2020-2025 | |
| Lilly USA, LLC | $122.93 | 2020-2024 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $114.88 | 2019-2024 | |
| Daiichi Sankyo INC. | $110.20 | 2019-2025 | Enhertu, Injectafer |
| Gilead Sciences, INC. | $103.65 | 2019-2024 | Trodelvy |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swee Jian Ngeow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.